We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
Redx Pharma
£25.5m placing extends runway to end-2022Nexstim
€0.9m prototype research project signedHutchison China MediTech
Canada Pension Plan invests $100m at $30 per ADSScancell
Redmile funding releases the brakesAllergy Therapeutics
Innovative G309 exploratory grass trial startsFutura Medical
MED3000: FDA details the scope of confirmatory studyMereo BioPharma
H120 results and corporate reviewScancell
Redmile endorses technologies with a further £30mNexstim
Pilot studies lift off in depression and painAllergy Therapeutics
Strong performances against strategic goals